MDGL Stock Madrigal Pharmaceuticals Inc - Complete Overview

Nasdaq / Pharmaceutical Products / Healthcare / MDGL Stock

Madrigal Pharmaceuticals Inc (MDGL) price per share as of 16 Mar 2018
Your sentiment
Shares Outstanding 14.23M
Avg Daily Volume 242.39K
Market Cap 1.81B
Volatility 61.18% HIGH


MDGL stock is a pharmaceutical products company traded on Nasdaq. It is valued at 1.81B US dollars. There are 14.23M shares outstanding which Madrigal Pharmaceuticals Inc issued to investors. Volatility of the stock is HIGH, and the daily volume is 61.18% stock on average. It brought investors a total return of 623.06% over the last 12 months. Madrigal Pharmaceuticals Inc stock is relatively cheap. It's P/E ratio is below the market average.

Madrigal Pharmaceuticals Inc (MDGL) STOCK PRICE PERFORMANCE


Earnings Per Share 0.00
Dividends Per Share 0.00
12 Months Price Performance High
Total Return High


Madrigal Pharmaceuticals: Well-Funded To Fill An Unmet Need

Madrigal stock is selling off today following an earnings report that showed the company burnt less money than expected.We look at the spending and show R&D expenses were less than we anticipated.2018

Viking Tumbles On Phase 2 Trial Delay, But Remains A Solid Buy

Viking Therapeutics announces delay in phase 2 VK2809 data, but presents itself as a buying opportunity. Like VK2809, a competing drug MGL-3196 using the same mechanism of action has already achieve p

3 Top Biotech Stocks to Buy in February

Want to cash in on the life sciences boom? Here are three stocks to check out.

Madrigal Pharmaceuticals: Elucidating The Positive Outcomes Of The Phase 2 Trial For Familial Hypercholesterolemia

Phase 2 trial that studied MGL-3196 in familial hypercholesterolemia met its primary outcome.Secondary endpoints were also achieved with high statistical significance.Madrigal remains a stellar long-t

Madrigal Pharmaceuticals: Buy The Dip

Shares have risen quite a bit since my December buy the secondary piece.I briefly remind readers of the bullish thesis and then move on to recent events.On Thursday, the company announced positive dat

Madrigal Continues Its Success With Another High Target Indication

Madrigal hits primary endpoint using MGL-3196 in midstage study for patients with a rare genetic disorder causing high levels of cholesterol.MGL-3196 has also shown early positive data in treating pat

Madrigal Pharmaceuticals Inc (MDGL) TECHNICAL INDICATORS

Name Value Action
RSI(14) 38.00 Sell
CMO(14) -24.00 Sell
ADX(14) 20.50 N/A
Williams %R -76.14 Overbought